Page 17 - Read Online

Page 12 of 13 Abughanimeh et al. J Cancer Metastasis Treat 2020;6:50 I http://dx.doi.org/10.20517/2394-4722.2020.110

results from a phase I study. Ann Oncol 2017;28:2559-66.
19. Masuda N, Fukuoka M, Kusunoki Y, et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell
lung cancer. J Clin Oncol 1992;10:1225-9.
20. Fujita A, Takabatake H, Tagaki S, Sekine K. Pilot study of irinotecan in refractory small cell lung cancer. Gan To Kagaku Ryoho
1995;22:889-93.
21. Kondo R, Watanabe S, Shoji S, et al. A phase II study of irinotecan for patients with previously treated small-cell lung cancer. Oncology
2018;94:223-32.
22. Smit EF, Fokkema E, Biesma B, Groen HJ, Snoek W, Postmus PE. A phase II study of paclitaxel in heavily pretreated patients with small-
cell lung cancer. Br J Cancer 1998;77:347-51.
23. Yamamoto N, Tsurutani J, Yoshimura N, et al. Phase II study of weekly paclitaxel for relapsed and refractory small cell lung cancer.
Anticancer Res 2006;26:777-81.
24. Smyth J, Smith I, Sessa C, et al. Activity of docetaxel (Taxotere) in small cell lung cancer. Eur J Cancer 1994;30:1058-60.
25. Evans TL, Cho BC, Udud K, et al. Cabazitaxel versus topotecan in patients with small-cell lung cancer with progressive disease during or
after first-line platinum-based chemotherapy. J Thorac Oncol 2015;10:1221-8.
26. Pietanza MC, Kadota K, Huberman K, et al. Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung
cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker. Clin Cancer Res 2012;18:1138-45.
27. Pietanza MC, Waqar SN, Krug LM, et al. Randomized, double-blind, phase II study of temozolomide in combination with either veliparib
or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer. J Clin Oncol 2018;36:2386-94.
28. Zauderer MG, Drilon A, Kadota K, et al. Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung
cancers with assessment of methylguanine-DNA methyltransferase. Lung Cancer 2014;86:237-40.
29. Johnson DH, Greco FA, Strupp J, Hande KR, Hainsworth JD. Prolonged administration of oral etoposide in patients with relapsed or
refractory small-cell lung cancer: a phase II trial. J Clin Oncol 1990;8:1613-7.
30. Einhorn LH, Pennington K, McClean J. Phase II trial of daily oral VP-16 in refractory small cell lung cancer: a Hoosier Oncology Group
study. Semin Oncol 1990;17:32-35.
31. Jassem J, Karnicka-młodkowska H, van Pottelsberghe C, et al. Phase II study of vinorelbine (Navelbine) in previously treated small cell
lung cancer patients. Eur J Cancer 1993;29:1720-2.
32. Drąg-Zalesińska M, Saczko J, Choromańska A, et al. Cisplatin and vinorelbine-mediated electrochemotherapeutic approach against
multidrug resistant small cell lung cancer (H69AR) in vitro. Anticancer Res 2019;39:3711-8.
33. Schmittel A, Knödler M, Hortig P, Schulze K, Thiel E, Keilholz U. Phase II trial of second-line bendamustine chemotherapy in relapsed
small cell lung cancer patients. Lung Cancer 2007;55:109-13.
34. Lammers PE, Shyr Y, Li CI, et al. Phase II study of bendamustine in relapsed chemotherapy sensitive or resistant small-cell lung cancer. J
Thorac Oncol 2014;9:559-62.
35. van der Lee I, Smit E, van Putten J, et al. Single-agent gemcitabine in patients with resistant small-cell lung cancer. Ann Oncol
2001;12:557-61.
36. Hoang T, Kim K, Jaslowski A, et al. Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer. Lung
Cancer 2003;42:97-102.
37. Yana T, Negoro S, Takada M, et al. Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung
cancer: West Japan Thoracic Oncology Group (WJTOG) study. Invest New Drugs 2007;25:253-8.
38. von Pawel J, Jotte R, Spigel DR, et al. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with
small-cell lung cancer. J Clin Oncol 2014;32:4012-9.
39. Spigel DR, Hainsworth JD, Lane CM, Clark B, Burris HA, Greco FA. Phase II trial of vinflunine in relapsed small cell lung cancer. J
Thorac Oncol 2010;5:874-8.
40. Gong J, Salgia R. Managing patients with relapsed small-cell lung cancer. J Oncol Pract 2018;14:359-66.
41. Hanna N, Bunn PA Jr, Langer C, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with
previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006;24:2038-43.
42. Goto K, Ohe Y, Shibata T, et al. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line
treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.
Lancet Oncol 2016;17:1147-57.
43. Antonia SJ, López-martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer
(CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol 2016;17:883-95.
44. Ready NE, Ott PA, Hellmann MD, et al. Nivolumab monotherapy and nivolumab plus ipilimumab in recurrent small cell lung cancer:
results from the CheckMate 032 Randomized Cohort. J Thorac Oncol 2020;15:426-35.
45. Reck M, Vicente D, Ciuleanu T, et al. Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent
small cell lung cancer (SCLC): results from CheckMate 331. Ann Oncol 2018;29:x43.
46. Ott PA, Elez E, Hiret S, et al. Pembrolizumab in patients with extensive-stage small-cell lung cancer: results from the phase Ib
KEYNOTE-028 study. J Clin Oncol 2017;35:3823-9.
47. Chung HC, Piha-Paul SA, Lopez-Martin, et al. Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC):
KEYNOTE-158. J Clin Oncol 2018;36:Abstract 8506
48. Chung HC, Piha-Paul SA, Lopez-Martin J, et al. Pembrolizumab after two or more lines of previous therapy in patients with recurrent or
metastatic SCLC: results from the KEYNOTE-028 and KEYNOTE-158 studies. J Thorac Oncol 2020;15:618-27.